Your browser is no longer supported. Please, upgrade your browser.
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own0.90% Shs Outstand114.02M Perf Week-14.38%
Market Cap868.83M Forward P/E- EPS next Y-0.98 Insider Trans-22.49% Shs Float108.52M Perf Month4.24%
Income-93.40M PEG- EPS next Q-0.25 Inst Own93.30% Short Float8.86% Perf Quarter6.57%
Sales21.80M P/S39.85 EPS this Y-4.10% Inst Trans13.52% Short Ratio16.73 Perf Half Y27.64%
Book/sh0.69 P/B11.04 EPS next Y- ROA-58.50% Target Price12.00 Perf Year52.40%
Cash/sh1.06 P/C7.22 EPS next 5Y19.90% ROE-141.00% 52W Range4.25 - 9.70 Perf YTD55.19%
Dividend- P/FCF- EPS past 5Y0.30% ROI-41.50% 52W High-21.48% Beta1.74
Dividend %- Quick Ratio2.00 Sales past 5Y-0.90% Gross Margin97.60% 52W Low79.29% ATR0.57
Employees85 Current Ratio2.00 Sales Q/Q-83.00% Oper. Margin- RSI (14)39.16 Volatility7.35% 6.90%
OptionableYes Debt/Eq0.85 EPS Q/Q-55.00% Profit Margin- Rel Volume1.19 Prev Close8.05
ShortableYes LT Debt/Eq0.43 EarningsNov 06 BMO Payout- Avg Volume574.72K Price7.62
Recom2.20 SMA20-13.91% SMA50-2.93% SMA20017.55% Volume681,956 Change-5.34%
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Oct-09-15Downgrade BofA/Merrill Buy → Neutral
Dec-17-18 06:42PM  Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-16-18 09:13AM  BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up Insider Monkey
Nov-27-18 08:55AM  New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-18 07:00AM  BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors GlobeNewswire +5.97%
Nov-16-18 07:00AM  BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology GlobeNewswire +7.66%
Nov-08-18 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Nov-06-18 08:30AM  BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:27AM  BioCryst: 3Q Earnings Snapshot Associated Press
07:00AM  BioCryst Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 07:00AM  BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire
Oct-30-18 10:33AM  Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline Zacks
Oct-23-18 04:15PM  BioCryst to Report Third Quarter 2018 Financial Results on November 6 GlobeNewswire
Oct-16-18 07:50AM  Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-12-18 09:17AM  Grifols (GRFS) Surges: Stock Moves 5.4% Higher Zacks +5.73%
Sep-25-18 04:15PM  BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-17-18 07:00AM  BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever GlobeNewswire
Sep-10-18 12:36PM  Here's Why BioCryst Pharmaceuticals Rose 21.3% in August Motley Fool
Sep-06-18 01:45PM  RTP pharma scores $35M contract to supply CDC American City Business Journals
07:37AM  BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy MarketWatch
07:00AM  CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile GlobeNewswire
Sep-05-18 08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga +5.27%
Sep-04-18 02:38PM  Inside The List: Highest-Paid Public Company CEOs American City Business Journals +6.01%
12:15PM  CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire
07:00AM  BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire
Aug-29-18 07:00AM  BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference GlobeNewswire
Aug-20-18 01:50PM  Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT Thomson Reuters StreetEvents
Aug-15-18 08:00AM  New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-07-18 03:38PM  BioCryst banks gross proceeds of $57.5M from offering American City Business Journals
07:30AM  BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:05AM  BioCryst: 2Q Earnings Snapshot Associated Press
06:00AM  BioCryst Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-06-18 04:01PM  BioCryst Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire
02:18PM  BioCryst gets FDA nod on key drug American City Business Journals
06:00AM  U.S. FDA Grants Fast Track Designation for BioCrysts BCX7353 GlobeNewswire
Aug-02-18 04:13PM  After Idera deal called off, BioCryst looks to raise $50M American City Business Journals +9.96%
02:40PM  Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today Motley Fool
08:54AM  The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga
Aug-01-18 09:59PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire -6.44%
04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
Jul-27-18 09:00AM  BioCryst to Announce Second Quarter 2018 Financial Results on August 7 GlobeNewswire
Jul-25-18 06:00PM  BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine GlobeNewswire
Jul-24-18 07:30AM  Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks ACCESSWIRE
Jul-17-18 08:37AM  Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga
Jul-11-18 05:33PM  Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today Motley Fool
02:34PM  Why Idera Pharmaceuticals Is Sinking Today Motley Fool
01:26PM  Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals American City Business Journals
11:56AM  Future of Idera's Cambridge office uncertain after failed merger American City Business Journals
09:23AM  Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie The Wall Street Journal
08:15AM  Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares Benzinga
08:00AM  BioCryst Provides Update on Strategy, Pipeline and Outlook Business Wire
Jul-10-18 06:00PM  No deal: BioCryst shareholders thwart merger with Idera American City Business Journals
05:36PM  [$$] Idera Pharmaceuticals and BioCryst Pharmaceuticals Terminate Merger Plans The Wall Street Journal
04:35PM  BioCryst's stock jumps, Idera drops as proposed merger called off MarketWatch
04:01PM  BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals Business Wire
Jun-25-18 07:15AM  Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks ACCESSWIRE
06:00AM  BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan GlobeNewswire
Jun-20-18 04:20PM  Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Jun-13-18 10:28AM  Idera Stock Down, Study on Dermatomyositis Candidate Fails Zacks
07:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-18 07:30AM  BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera Business Wire
May-29-18 08:00AM  BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress GlobeNewswire
May-24-18 12:30PM  BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema GlobeNewswire
06:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-17-18 09:00AM  Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks ACCESSWIRE
May-14-18 09:51AM  Edited Transcript of BCRX earnings conference call or presentation 8-May-18 3:00pm GMT Thomson Reuters StreetEvents +9.27%
May-10-18 07:05AM  Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient ACCESSWIRE
May-08-18 10:11AM  Will BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Grow In The Years Ahead? Simply Wall St. -9.53%
09:37AM  BioCryst: 1Q Earnings Snapshot Associated Press
06:00AM  BioCryst Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 08:24AM  BioCryst lands European approval for flu treatment American City Business Journals +5.94%
May-01-18 06:00AM  BioCryst Receives European Medicines Agency Approval for ALPIVAB for the Treatment of Influenza GlobeNewswire
Apr-26-18 08:20AM  New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:00AM  BioCryst to Announce First Quarter 2018 Financial Results on May 8 GlobeNewswire
Apr-10-18 02:51PM  Vote on proposed merger of biopharm firms pushed back American City Business Journals
07:30AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger Business Wire
Apr-03-18 02:38PM  Why another BioCryst shareholder plans to vote against Idera merger American City Business Journals +5.86%
Apr-02-18 08:13AM  RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals PR Newswire
08:00AM  BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals Business Wire
Mar-29-18 05:21AM  Edited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMT Thomson Reuters StreetEvents
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-23-18 11:00PM  Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX) GlobeNewswire
Mar-22-18 12:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-20-18 02:58PM  15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies TheStreet.com
Mar-15-18 06:00AM  BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire
Mar-09-18 07:50AM  Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid ACCESSWIRE
Feb-28-18 06:00AM  BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire
Feb-27-18 09:35AM  Does BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Growth Make It An Outperformer? Simply Wall St.
09:31AM  BioCryst reports 4Q loss Associated Press
08:30AM  BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
08:00AM  BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-26-18 08:45AM  BioCryst, Idera outline specifics on merger value American City Business Journals
08:30AM  Options Traders Expect Huge Moves in BioCryst (BCRX) Stock Zacks
Feb-20-18 06:00AM  BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27 GlobeNewswire
Feb-19-18 01:00PM  BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences GlobeNewswire
Feb-16-18 01:20PM  Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire
Feb-05-18 08:39AM  Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock? Zacks
Jan-23-18 09:26AM  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall Zacks
06:35AM  Cambridge's Idera plans eventual move out of state after merger with BioCryst American City Business Journals
Jan-22-18 04:05PM  BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love Motley Fool
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Powell LynneSenior VP - CCODec 10Option Exercise3.224,00012,8802,000Dec 12 04:13 PM
Powell LynneSenior VP - CCODec 10Sale9.064,00036,2400Dec 12 04:13 PM
STAAB THOMAS R IISenior Vice President and CFODec 04Sale9.453,92237,063133,461Dec 06 04:30 PM
Stonehouse Jon PPresident & CEODec 03Option Exercise1.2080,00096,000807,674Dec 06 04:34 PM
Stonehouse Jon PPresident & CEODec 03Sale9.1280,000729,600727,674Dec 06 04:34 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 30Option Exercise1.4225,00035,500122,243Dec 04 04:11 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 30Sale9.0744,290401,71077,953Dec 04 04:11 PM
Erck Stanley CDirectorNov 28Option Exercise1.498,33312,41648,333Nov 30 04:02 PM
STAAB THOMAS R IISenior Vice President and CFONov 23Option Exercise3.783,50013,230140,883Nov 26 04:19 PM
STAAB THOMAS R IISenior Vice President and CFONov 23Sale9.663,50033,810137,383Nov 26 04:19 PM
STAAB THOMAS R IISenior Vice President and CFONov 21Option Exercise4.4812,00053,710144,383Nov 26 04:19 PM
Powell LynneSenior VP - CCONov 21Option Exercise3.2212,00038,64014,455Nov 26 04:22 PM
Powell LynneSenior VP - CCONov 21Sale9.0514,455130,8400Nov 26 04:22 PM
STAAB THOMAS R IISenior Vice President and CFONov 21Sale9.2212,000110,610137,383Nov 26 04:19 PM
STAAB THOMAS R IISenior Vice President and CFONov 20Option Exercise3.4511,12338,405143,883Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 20Option Exercise3.229,12729,38917,732Nov 21 04:51 PM
Powell LynneSenior VP - CCONov 20Sale8.5615,277130,7142,455Nov 21 04:51 PM
STAAB THOMAS R IISenior Vice President and CFONov 20Sale8.6811,12396,494137,383Nov 21 04:48 PM
STAAB THOMAS R IISenior Vice President and CFONov 19Option Exercise3.7875284137,458Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 19Option Exercise3.221936218,798Nov 21 04:51 PM
Powell LynneSenior VP - CCONov 19Sale8.301931,6028,605Nov 21 04:51 PM
STAAB THOMAS R IISenior Vice President and CFONov 19Sale8.3075623137,383Nov 21 04:48 PM
Powell LynneSenior VP - CCONov 08Option Exercise3.225,28017,00213,885Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 08Option Exercise3.3213,41544,485148,496Nov 09 04:14 PM
STAAB THOMAS R IISenior Vice President and CFONov 08Sale8.1313,415109,011137,383Nov 09 04:14 PM
Powell LynneSenior VP - CCONov 08Sale8.155,28043,0328,605Nov 09 04:11 PM
Powell LynneSenior VP - CCONov 07Option Exercise3.223009668,905Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 07Option Exercise3.226722,164138,055Nov 09 04:14 PM
STAAB THOMAS R IISenior Vice President and CFONov 07Sale8.006725,376137,383Nov 09 04:14 PM
Powell LynneSenior VP - CCONov 07Sale8.003002,4008,605Nov 09 04:11 PM
STAAB THOMAS R IISenior Vice President and CFONov 05Option Exercise3.22215692137,598Nov 07 04:03 PM
Powell LynneSenior VP - CCONov 05Option Exercise3.221003228,705Nov 07 04:05 PM
Powell LynneSenior VP - CCONov 05Sale8.001008008,605Nov 07 04:05 PM
STAAB THOMAS R IISenior Vice President and CFONov 05Sale8.002151,720137,383Nov 07 04:03 PM
STAAB THOMAS R IISenior Vice President and CFONov 02Option Exercise3.4010,85636,916144,739Nov 06 04:04 PM
Powell LynneSenior VP - CCONov 02Option Exercise3.221,0003,2209,605Nov 06 04:07 PM
Powell LynneSenior VP - CCONov 02Sale8.001,0008,0008,605Nov 06 04:07 PM
STAAB THOMAS R IISenior Vice President and CFONov 02Sale7.8410,85685,090137,383Nov 06 04:04 PM
Powell LynneSenior VP - CCONov 01Sale7.511,54411,5958,605Nov 05 01:17 PM
STAAB THOMAS R IISenior Vice President and CFOOct 19Option Exercise3.783,15011,907140,533Oct 23 01:34 PM
STAAB THOMAS R IISenior Vice President and CFOOct 19Sale7.453,15023,468137,383Oct 23 01:34 PM
Powell LynneSenior VP - CCOOct 19Sale7.5010075010,149Oct 23 01:31 PM
STAAB THOMAS R IISenior Vice President and CFOOct 03Option Exercise3.271,0723,508138,355Oct 04 01:09 PM
STAAB THOMAS R IISenior Vice President and CFOOct 03Sale7.281,0727,802137,383Oct 04 01:09 PM
STAAB THOMAS R IISenior Vice President and CFOOct 02Option Exercise3.438,77830,085142,911Oct 04 01:09 PM
STAAB THOMAS R IISenior Vice President and CFOOct 02Sale7.248,77863,556137,383Oct 04 01:09 PM
Sheridan William PSenior VP - CMOAug 09Option Exercise1.4262,50088,75085,713Aug 13 10:07 AM
Sheridan William PSenior VP - CMOAug 09Sale7.0362,500439,37523,213Aug 13 10:07 AM
Sheridan William PSenior VP - CMOJun 01Option Exercise2.5842,112108,64963,170Jun 05 03:07 PM
Sheridan William PSenior VP - CMOJun 01Sale6.3042,112265,30621,058Jun 05 03:07 PM
Stonehouse Jon PPresident & CEOMay 17Option Exercise1.4270,427100,006725,519May 21 09:31 AM
Barnes Alane PVP, General Counsel & Corp SecMay 15Option Exercise1.4212,50017,75098,268May 17 09:25 AM
Babu Yarlagadda SSenior VP - Drug DiscoveryMar 06Option Exercise3.2630,00097,800120,618Mar 08 03:48 PM
Stonehouse Jon PPresident & CEOFeb 28Option Exercise3.2656,949185,654698,316Mar 02 02:23 PM
Barnes Alane PVP, General Counsel & Corp SecFeb 28Option Exercise3.266,70921,87185,768Mar 02 02:21 PM